SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 50.73-5.2%Nov 19 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Biomaven who wrote (4025)6/6/2001 10:48:17 AM
From: Biomaven  Read Replies (1) of 52153
 
So it looks like BMY will end up with DuPont. One interesting sidelight is the effect this will have on KOSP. BMY of course already has a statin, so this will likely conflict with the KOSP deal. Usually in these circumstances the partner in KOSP's position has come out well. (Think of FRX and Celexa as the best example). Only caveat is whether KOSP will be able to find another decent partner.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News